4 ms·
Interesting contrast to the world of biotech VC where the IPO and M&A environment has been strong since 2013. More IPOs and big M&A deals than tech despite only
by aaavl2821 8y ago
Interesting contrast to the world of biotech VC where the IPO and M&A environment has been strong since 2013. More IPOs and big M&A deals than tech despite only getting 1/5 of funding
Seems this startup bull cycle has been driven by M&A where the late 1990s was driven by retail investors. However the tech acquirers seemed to have slowed down since 2010-2014 while biotech acquirers have been doing a steady number of billion dollar plus buyouts
- sjg007 8y agoBiotech is more traditional.. VCs assume less risk overall even though materials may be more expensive than a straight tech company. In the former you get something that works and the FDA approves in the latter you are going for users.. in some sense gaining users depends on vanity like total funding which drives press etc... This might be a weak hypothesis.. dunno. Other companies in the space that are not retail consumer oriented with high valuations seem to suffer.